Analyst Price Target is $80.33
▲ +181.77% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Applied Molecular Transport in the last 3 months. The average price target is $80.33, with a high forecast of $92.00 and a low forecast of $74.00. The average price target represents a 181.77% upside from the last price of $28.51.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Applied Molecular Transport.
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.